Drug Manufacturers
5Vote!
Julie Brill Nominated to FTC: A Message to Drug Manufacturers?
The IN VIVO Blog (Free subscription) | 11/19/2009
The Obama administration may have sent a subtle message to drug manufacturers Monday, when it nominated Julie Brill to be one of two new commissioners at the Federal Trade Commission. The message? Make sure your marketing practices don’t collide with consumers’ best interests. Brill has overseen consumer protection for states since 1988, with a major emphasis on watching over the pharmaceutical...
Videos
3Vote!
US Committee leaders call for GAO analysis of recent prescription drug price increases
thepharmaletter.com (Free subscription) | 11/19/2009
Following recent allegations in the New York Times, and rebuttals by the US research-based pharmaceutical industry (The Pharma Letter November 18), leaders of the US House Ways and Means and Energy and Commerce Committees have sent a letter to the Government Accountability Office (GAO) requesting an expedited report on recent trends in prescription drug pricing.
3Vote!
Isis Extends Timeline on Cholesterol-Lowering Drug, FDA Delays Review of Cadence Pain Reliever, Fate Therapeutics Raises $30 Million, & More San Diego Life Sciences News
Xconomy (Free subscription) | 11/19/2009
Drug development programs got extended at two San Diego life sciences companies, while others had some good news on the fund-raising front. We wrap it all up for you here. —Fate Therapeutics, a startup working to supply “industrialized” stem cells for the pharmaceutical industry without using embryos, said it raised $30 million in venture capital. That [...]
5Vote!
Pharmaceutical Industry Market Review
bharatbook | 11/20/2009
The total UK market for pharmaceuticals was worth an estimated £13.65bn in 2007. Prescription-only medicines accounted for most of this figure, with a smaller share being taken by over-the-counter (OTC) pharmaceuticals. ( http://www.bharatbook.com/detail.asp?id=75736&rt=Pharmaceutical-Industry-Market-Review.html ) The UK is home to the most important pharmaceutical industry in Europe in terms
3Vote!
Executive Moves: Frontage
Contract Pharma Breaking News (Free subscription) | yesterday
Samir Ghodbane, Ph.D. , has been appointed as the new general manager of CMC services and CTM manufacturing at Frontage . Dr. Ghodbane has extensive experience and expertise in product development and technical operations spanning the complete product development cycle, as well as a comprehensive understanding of branded and generic pharmaceutical environments. He has led drug development and technical...
6Vote!
Let the "Historic" Debate Begin
medinnovationblog (Free subscription) | yesterday
November 20 - When the Senate votes tomorrow whether to engage in further health reform steps, the stage is set for an historic debate. Before we engage in this debate, let us be clear what this debate is about. It is about, • the balance of power between government controls and individual freedoms. • how to make health costs for government and individuals “ sustainable" and how...
3Vote!
Dan Loeb's Third Point Starts New Stakes In Popular (BPOP), TransDigm (TDG), & Health Net (HNT)
market folly (Free subscription) | 11/19/2009
This is the third quarter 2009 edition of our hedge fund portfolio tracking series. If you're unfamiliar with tracking hedge fund movements or SEC filings, check out our series preface on hedge fund 13F filings . Next up in our series is Dan Loeb's Third Point LLC. Third Point is a multi-billion dollar hedge fund that has seen annual returns greater than 15% since inception. Manager Dan Loeb focuses...
5Vote!
Moody's gives negative view on pharma credit
Seattle Post-Intelligencer (Free subscription) | 11/19/2009
NEW YORK -- Moody's Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won't be able to fully replace revenue from best-sellers that go off-patent.
4Vote!
Perrigo Company To Present at the Sidoti Emerging Growth Conference
PR News Wire (Free subscription) | 11/19/2009
ALLEGAN, Mich., Nov. 19 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Sidoti Emerging Growth Conference on Friday, November 20, at 3:15 p.m. (EST) at the Grand Hyatt Hotel in New York City.
4Vote!
Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
Business Wire (Free subscription) | 11/19/2009
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December. “We have had a long and productive drug discovery relationship with Organon and Schering-Plough (which...
3Vote!
Sex and pharmaceuticals: Arousing interest
The Economist (Free subscription) | 11/19/2009
The search continues for a pill that will lift a woman’s libido BACK in the 1990s a drug firm called Pfizer thought it had a treatment for angina. Unfortunately, the new medicine failed its clinical trials. But a curious side-effect was seen in those trials—and Viagra was born. It has helped make Pfizer into a pharmaceutical powerhouse and, since then, people have wondered if what is sauce...
3Vote!
NHS turn down Liver Cancer drug on cost
Andrew Reeves' running blog (Free subscription) | 11/19/2009
I know that the National Institute for Health and Clinical Excellence (NICE) has to think of all the patients and the costs of all drugs for the NHS. However, surely if there is a drug available that helps liver cancer patients live longer then that has to be a price worth paying. Not everything in life should be about cost, and perhaps NICE and the Government, who claim they are taking cancer seriously...
4Vote!
FDA Advisory Committee Finds Data Support the Safety and Effectiveness of Prevnar 13™ Vaccine for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children
Business Wire (Free subscription) | 11/19/2009
NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]),...
3Vote!
AstraZeneca applies for US approval for blood clot preventer Brilinta
Canadian Online Health News (Free subscription) | 11/19/2009
LONDON - AstraZeneca PLC said Thursday it has applied to U.S. regulators to market its blood clot preventer Brilinta, a potential new big seller for the company. AstraZeneca submitted a new drug application to the U.S.
The 3 latest articles published by users on Drug Manufacturers :
5Vote!
Pharmaceutical Industry Market Review
bharatbook | 11/20/2009
The total UK market for pharmaceuticals was worth an estimated £13.65bn in 2007. Prescription-only medicines accounted for most of this figure, with a smaller share being taken by over-the-counter (OTC) pharmaceuticals. ( http://www.bharatbook.com/detail.asp?id=75736&rt=Pharmaceutical-Industry-Market-Review.html ) The UK is home to the most important pharmaceutical industry in Europe in terms of development
3Vote!
ERP Products in india
eresource infotech | 11/09/2009
ERP Products in india One stop for all your ERP software solution ERESOURCEERP Products An effective solution for Pharmaceutical Industry For any Pharmaceutical ERP, compliance with GMP & FDA requirement considered as prime importance. Though 21 CFR Part II has been launched, many companies yet to tackle its practical implementation. User-friendly Eresource ERP is compliant to all statutory regulation...
4Vote!
Middle East and Africa pharmaceutical market poised to grow 11% annually till 2012
bharatbook | 10/30/2009
The Middle East and Africa pharmaceutical industry is entering a new era, with the development of infrastructure system and rapidly changing regulations. The industry is blessed with several advantages like high prevalence of diseases, huge population base and many more, reflecting bight prospects of growth in coming years. With these supportive factors, the pharmaceutical industry in the MEA region